Navigation Links
Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
Date:1/15/2009

Company Outlines Steps Taken to Reduce Expenses in Light of Economic Downturn and Challenging Credit Environment

WESTFORD, Mass., Jan. 15 /PRNewswire-FirstCall/ -- Cynosure, Inc. (NASDAQ: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced preliminary financial results for the fourth quarter ended December 31, 2008.

Cynosure expects to report fourth-quarter 2008 revenues of $25 million to $26 million, reflecting the global economic downturn and weakening credit environment. This compares with revenues of $36.6 million for the fourth quarter of 2007. The company expects to report a GAAP net loss for the fourth quarter of 2008 of $2.2 million to $2.7 million, or $0.17 to $0.21 per share, compared with GAAP net income of $5.3 million, or $0.41 per diluted share, for the same period in 2007. Financial results for the fourth quarter of 2008 are expected to include a bad debt charge of approximately $2.5 million. This charge is related to uncollectible accounts from certain customers affected by the overall economic environment and the tightening of credit markets, which subsequently caused a number of practitioners to be unable to meet their payment obligations. Cash, cash equivalents, marketable securities and investments at December 31, 2008 are expected to increase approximately $3 million to approximately $95 million from $92.3 million as of September 30, 2008.

These preliminary financial results are unaudited. Cynosure plans to announce its full audited financial results for the three and 12 months ended December 31, 2008 before the opening of the market on Tuesday, February 10, 2009.

"The effect of the global economic crisis on the aesthetic laser industry has been swift and severe, hampering the ability of many prospecti
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
2. Cynosure to Announce Second-Quarter 2008 Financial Results on July 29
3. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
4. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
5. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
6. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
7. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
8. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting
9. CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit
10. Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
11. Cynosure to Announce Third-Quarter 2007 Financial Results on November 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Park, NJ (PRWEB) , ... August 03, 2015 ... ... pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” ... software architects, engineers and technology leaders from healthcare organizations with access to the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA ... recent years, according to the American Dental Association. According to a study by the ... from 1.1 million in a single year to 2.2 million a year. Dentists and ...
(Date:8/3/2015)... ... 2015 , ... Illinois Health & Science (IHS) has completed the purchase of ... all of IBAM NA’s cyclotron sites and research and development facilities. , ... as well as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President ...
(Date:8/3/2015)... ... , ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing ... years of suffering and using medications with strong side effects. This had already forced ... time off or wait longer hours in the waiting rooms. Instead, he went home ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... a leading provider of medical information, risk management and investigative services, has ... and direction toward focused, expert information solutions that improve business outcomes for ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... named Jim Bohnsack vice,president of healthcare information solutions, a ... in the Western region of the United States. , ... president of healthcare,for TransUnion. , ... relationships,with key supporting institutions and organizations will be an ...
... will see Japan,s Trinity Design Corporation Ltd, becoming a reseller and ... already negotiated its first Rhapsody sale with the Kobe Circulation Clinic, ... quality medical care. , ... Auckland, NZ (PRWEB) ...
... LLP, founded in 1968, has successfully represented victims of negligence, personal ... , ... (PRWEB) January 6, 2008 -- Smiley & ... personal injury, wrongful death and medical malpractice for over 40 years. ...
... knew there had to be a better way. He and ... how best to engage patients with chronic diseases in effective ... Chronic Care Model. More than 1,500 U.S. and international medical ... evidence on how the Model performs in practice confirms that ...
... Technology Company today announces the award of a network IP-Based ... ... Washington, D.C. (PRWEB) December 15, 2008 -- ... Notification Technology Company, today announces the award of a network ...
... and surgeon medical liability, launched its first Southeast Legal Summit ... have the most current information regarding the defense of medical ... ... California (Vocus) December 17, 2008--- The Doctors Company , ...
Cached Medicine News:Health News:TransUnion Names New Vice President of Healthcare Information Solutions 2Health News:Orion Health Signs Trinity Design for Japanese Market 2Health News:Orion Health Signs Trinity Design for Japanese Market 3Health News:Prominent New York City Personal Injury Law Firm Founded in 1968 Stays at the Cutting Edge with Launch of Video-Based Website 2Health News:Chronic Care Model helps improve people’s health and care 2Health News:Chronic Care Model helps improve people’s health and care 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 2Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 3Health News:Berkshire Medical Center Selects Desktop Alert for Mass Notification Solutions 4Health News:The Doctors Company Launches Southeast Legal Summit to Provide Industry's Best Claims Defense for Physicians 2
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... July 31, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... its previously announced underwritten public offering of 7,666,667 ... offering price of $11.25 per share. The shares ... shares issued upon the exercise in full by ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... March 16 Healthpoint today announced that it has ... of HP802-247 in venous leg ulcers. HP802-247 is a ... is designed to determine the effectiveness of two cell ... with standard care, compared to placebo plus standard care, ...
... Aims To Enhance Precision and Reduce High Failure ... Hamilton, N.J., March 16 ICON (Nasdaq: ... outsourced development services to the pharmaceutical, biotechnology and ... in centralized psychiatric patient evaluation, today announced that ...
Cached Medicine Technology:Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 2Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers 3ICON and MedAvante Sign Alliance Agreement 2
... II (Low Melt), A low temperature ... melting temperature , Optimal for in-gel restriction ... forms a very manageable clear gel that ... Melts at approximately 65°C and remains fluid ...
... for molecular screening that improves resolution of small ... are:, High resolution of PCR and DNA ... of the gel, enhancing visibility. , Better handling ... structure and higher gel strength. The chances of ...
... Molecular Biology Grade, is used ... nucleic acids. It can be ... from 0.2 to 40 kb., ... is tested and certified to ...
Inquire...
Medicine Products: